Literature DB >> 19889756

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Annalisa Macagno1, Nadia L Bernasconi, Fabrizia Vanzetta, Erica Dander, Antonella Sarasini, Maria Grazia Revello, Giuseppe Gerna, Federica Sallusto, Antonio Lanzavecchia.   

Abstract

Human cytomegalovirus (HCMV) is a widely circulating pathogen that causes severe disease in immunocompromised patients and infected fetuses. By immortalizing memory B cells from HCMV-immune donors, we isolated a panel of human monoclonal antibodies that neutralized at extremely low concentrations (90% inhibitory concentration [IC(90)] values ranging from 5 to 200 pM) HCMV infection of endothelial, epithelial, and myeloid cells. With the single exception of an antibody that bound to a conserved epitope in the UL128 gene product, all other antibodies bound to conformational epitopes that required expression of two or more proteins of the gH/gL/UL128-131A complex. Antibodies against gB, gH, or gM/gN were also isolated and, albeit less potent, were able to neutralize infection of both endothelial-epithelial cells and fibroblasts. This study describes unusually potent neutralizing antibodies against HCMV that might be used for passive immunotherapy and identifies, through the use of such antibodies, novel antigenic targets in HCMV for the design of immunogens capable of eliciting previously unknown neutralizing antibody responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889756      PMCID: PMC2798344          DOI: 10.1128/JVI.01809-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Genetic content of wild-type human cytomegalovirus.

Authors:  Aidan Dolan; Charles Cunningham; Ralph D Hector; Aycan F Hassan-Walker; Lydia Lee; Clare Addison; Derrick J Dargan; Duncan J McGeoch; Derek Gatherer; Vincent C Emery; Paul D Griffiths; Christian Sinzger; Brian P McSharry; Gavin W G Wilkinson; Andrew J Davison
Journal:  J Gen Virol       Date:  2004-05       Impact factor: 3.891

2.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

Authors:  D R Snydman; B G Werner; B Heinze-Lacey; V P Berardi; N L Tilney; R L Kirkman; E L Milford; S I Cho; H L Bush; A S Levey
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

3.  Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.

Authors:  D J Winston; W G Ho; C H Lin; K Bartoni; M D Budinger; R P Gale; R E Champlin
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

4.  Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain.

Authors:  Adam L Feire; Heidi Koss; Teresa Compton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-19       Impact factor: 11.205

5.  Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes.

Authors:  Gabriele Hahn; Maria Grazia Revello; Marco Patrone; Elena Percivalle; Giulia Campanini; Antonella Sarasini; Markus Wagner; Andrea Gallina; Gabriele Milanesi; Ulrich Koszinowski; Fausto Baldanti; Giuseppe Gerna
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.

Authors:  R M Condie; R J O'Reilly
Journal:  Dev Biol Stand       Date:  1982

7.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors:  A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

Review 8.  Pathogenesis of human cytomegalovirus infection and cellular targets.

Authors:  Giuseppe Gerna; Fausto Baldanti; M Grazia Revello
Journal:  Hum Immunol       Date:  2004-05       Impact factor: 2.850

9.  Human monoclonal antibodies neutralizing human cytomegalovirus.

Authors:  Y Masuho; Y Matsumoto; T Sugano; S Fujinaga; Y Minamishima
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

10.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

Authors:  Elisabetta Traggiai; Stephan Becker; Kanta Subbarao; Larissa Kolesnikova; Yasushi Uematsu; Maria Rita Gismondo; Brian R Murphy; Rino Rappuoli; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  163 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

Review 2.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

3.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

4.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 5.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

6.  Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Martin Zydek; Lenore Pereira
Journal:  Am J Pathol       Date:  2016-09-13       Impact factor: 4.307

Review 7.  What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Authors:  Dennis R Burton
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

8.  Coding potential of UL/b' from the initial source of rhesus cytomegalovirus Strain 68-1.

Authors:  Rachel B Gill; J Jason Bowman; Tammy Krogmann; Kurt Wollenberg; David M Asher; Jeffrey I Cohen
Journal:  Virology       Date:  2013-10-02       Impact factor: 3.616

9.  Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Authors:  Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer.

Authors:  Anna Kabanova; Jessica Marcandalli; Tongqing Zhou; Siro Bianchi; Ulrich Baxa; Yaroslav Tsybovsky; Daniele Lilleri; Chiara Silacci-Fregni; Mathilde Foglierini; Blanca Maria Fernandez-Rodriguez; Aliaksandr Druz; Baoshan Zhang; Roger Geiger; Massimiliano Pagani; Federica Sallusto; Peter D Kwong; Davide Corti; Antonio Lanzavecchia; Laurent Perez
Journal:  Nat Microbiol       Date:  2016-06-06       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.